Human Microbiome Market to Surpass US$ 201.5 Billion by 2026 - Coherent Market Insights

Global Human Microbiome Market, by Product Type (Foods, Diagnostic Devices/Kits, Drugs, and Others), by Application (Therapeutics and Diagnostics), by Disease Indication (Gastrointestinal Disorders, Metabolic Disorders, Women Health, Cancer, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 46,913.4 million in 2017, and is projected to exhibit a CAGR of 17.5% over the forecast period (2018 – 2026), as highlighted in a new report published by . High number of collaboration activities between key players and academia Increasing number of collaboration activities between various players in the market and between different players and research institutes is expected to aid in the expansion and development of novel medicines for variety of diseases. For instance, in 2017, AOBiome secured US$ 30 million investment for advancing clinical research on systemic and topical inflammatory disorders using novel bacterial platform from iCarbonX. It is evident that such efforts are accelerating the research and development of microbiome platform. Similarly, in 2017, Stanford University School of Medicine and Vedanta Biosciences Inc. entered in research collaboration to focus on food allergies in children and on patients with C. difficile infection or graft-versus-host disease Browse 36 Market Data Tables and 35 Figures spread through 220 Pages and in-depth TOC on ‘Human Microbiome Market’- Global Forecast to 2026, by Product Type (Foods, Diagnostic Devices/Kits, Drugs, and Others), by Application (Therapeutics, and Diagnostics), by Disease Indication (Gastrointestinal Disorders, Metabolic Disorders, Women Health, Cancer, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) To know the latest trends and insights prevalent in the Human Microbiome market, click the link below: https://www.coherentmarketinsights.com/market-insight/human-microbiome-market-182 Growing incidence of disease conditions in which human microbiome product is used. According to data given by Centre for Disease Control and Prevention in October 2017, Clostridium difficile infection (CDI) is one of the most common healthcare-associated infections in the China and Hong Kong, affecting around 36.1 cases/100,000 person in 2014, an annual increase of 26%. According to study published in Clinical Infectious Disease journal in 2015, about 25% to 33% of antibiotic-associated diarrhea and 90% of pseudomembranous enteritis are caused by CDI. Key Takeaways of the Human Microbiome Market:

• The global human microbiome market is expected to exhibit a CAGR of 17.5% over the forecast period, owing to increasing prevalence of cardiopulmonary conditions, cancer, and renal diseases.
• Among product type, the foods segment held a dominant position in the human microbiome market in 2017, owing to high adoption of probiotics-based food and beverages for maintaining balance of microbiomes
• Among disease type, cancer disease held a dominant position in the human microbiome market in 2017. In September 2018, World Health Organization (WHO), stated that cancer is the second largest cause of deaths globally.
• Among application, diagnostics segment held a dominant position in the human microbiome market in 2017, as emergence of diagnosis in early stage of cancer and other diseases is proven to be beneficial in disease management.
• Key players operating in the global human microbiome market include Enterome Bioscience, Yakult Honsha Co., Ltd., DuPont, Metabiomics Corporation, ViThera Pharmaceuticals, Second Genome Inc., AOBiome LLC, Seres Therapeutics, uBiome, Inc., Rebiotix, Inc., Synthetic Biologics, Inc., MicroBiome Therapeutics LLC, Vedanta BioSciences, Osel, Inc., and Merck & Co., Inc.